After an apparent cure, a gene editing company struggles to repeat the magic

iECURE, a gene editing startup, initially celebrated success with its experimental gene therapy that appeared to cure a baby of a severe genetic disorder. However, recent trials involving a larger cohort of infants have not replicated these promising results, raising concerns about the therapy's efficacy and the challenges of scaling such treatments.